SELLAS Life Sciences Group, Inc.
SLS
$12.78
$0.423.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.93% | 4.86% | -17.50% | -5.44% | -8.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.10% | 4.59% | -16.68% | -14.45% | -18.74% |
| Operating Income | -17.10% | -4.59% | 16.68% | 14.45% | 18.74% |
| Income Before Tax | -23.62% | -8.59% | 13.01% | 19.63% | 23.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.62% | -8.59% | 13.01% | 19.63% | 23.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.62% | -8.59% | 13.01% | 19.63% | 23.75% |
| EBIT | -17.10% | -4.59% | 16.68% | 14.45% | 18.74% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 34.14% | 40.54% | 53.56% | 59.67% | 64.84% |
| Normalized Basic EPS | 40.77% | 44.58% | 56.18% | 57.56% | 63.24% |
| EPS Diluted | 34.14% | 40.60% | 53.59% | 59.69% | 64.85% |
| Normalized Diluted EPS | 40.77% | 44.58% | 56.18% | 57.56% | 63.24% |
| Average Basic Shares Outstanding | 86.06% | 81.03% | 78.18% | 82.98% | 103.31% |
| Average Diluted Shares Outstanding | 86.06% | 81.03% | 78.18% | 82.98% | 103.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |